Despite the low number of MuSK-Ab positive patients included in these clinical trials, the available data suggest that FcRn inhibitors pose a promising therapeutic option for MuSK-MG and can be considered in refractory patients with unsatisfactory response to rituximab (25). The gene discussed is MUSK; the disease is myasthenia gravis.